Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

Leukemia·2026
Same author

European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms: reponse to the comments from the Francophone Group of Hematological Cytogenetics (GFCH).

Leukemia·2020
Same author

Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.

Leukemia·2020
Same author

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.

Leukemia·2019
Same author

European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms.

Leukemia·2019
Same author

Dreams can come true: the first steps toward a peripheral blood screening test for the early detection of tumors have been taken.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Related Experiment Video

Updated: Jun 24, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Interactive diagnostics in the indication to allogeneic SCT in AML.

U Bacher1, C Haferlach, S Schnittger

  • 1Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany. u.bacher@uke.de

Bone Marrow Transplantation
|April 14, 2009
PubMed
Summary

Defining the exact subentity and risk category is crucial for allogeneic stem cell transplantation (allo-SCT) in acute myeloid leukemia (AML). Comprehensive diagnostics combining genetic markers and methods optimize patient selection for allo-SCT.

More Related Videos

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Related Experiment Videos

Last Updated: Jun 24, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Acute myeloid leukemia (AML) is a heterogeneous disease.
  • Accurate risk stratification is essential for guiding treatment decisions, including allogeneic stem cell transplantation (allo-SCT).

Purpose of the Study:

  • To outline a comprehensive diagnostic approach for optimizing the indication of allo-SCT in AML.
  • To highlight the role of various diagnostic methods in defining AML subentities and risk categories.

Main Methods:

  • Cytomorphology
  • Cytogenetics
  • Fluorescence in situ hybridization (FISH)
  • Molecular genetics (PCR for mutations like FLT3-ITD, MLL-PTD, NPM1, CEBPA, WT1)
  • Immunophenotyping
  • Minimal residual disease (MRD) monitoring

Main Results:

  • Established prognostic karyotype groups exist.
  • Rare recurrent aberrations like t(8;16), inv(3), and t(6;9) are unfavorable.
  • Molecular mutations (FLT3-ITD, MLL-PTD, NPM1, CEBPA) in normal karyotype AML guide allo-SCT selection in >85% of cases.
  • Novel markers like WT1 mutations may aid risk stratification.

Conclusions:

  • Optimizing allo-SCT indication requires a multi-faceted diagnostic approach.
  • Continuous interaction between diagnostic methods and genetic markers is necessary for refining patient selection.
  • Further validation of immunophenotyping's role in allo-SCT indication is needed.